‹ ›
MYP_047361
← PREVIOUS NEXT → BACK
Basic Information
T-290821
Antimicrobial
Antiviral
Antiviral ▸ Anti-HIV
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition ▸ Fusion inhibitor
Standard
38 amino acids
C200H320N56O61
Standard
Sequence
TTWEAWDRAIAEYAARIEALIRALQELQEKNEAILREL
Physicochemical Analysis
4485.02 Da
4.64
-3.58
-3.79
-0.0943
-0.36
0.73
-0.07
59.02
113.42
0.0789
12490.00
12490.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1933.58
-13.82
68.0
58.0
152.0
317.0
5.0
40.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0125830 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral
098-T20 virus
0.154 μg/mL
IC50
Male cynomolgus monkey blood plasma (Intravenous), in vivo; 34560 s
PaperDesign of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus PMID17640899 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17640899/
RECORD: Rec_0126741 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral
HIV-1 098-T1249
PMID17640899 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17640899/
RECORD: Rec_0176001 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Amidation
Bio-Activity Profile
Antiviral Anti-HIV Fusion inhibition
HIV IIIB | CEM4 cells
0.01449 μM
IC50
Mammalian: 7.2 h; Yeast: >20 h; E. coli: >10 h
PaperDesign of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. | Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK. | Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. | DOI:10.1073/pnas.0701478104 | PMID:17640899 PMID17640899 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17640899/
RECORD: Rec_0220019 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HIV fusion inhibitor
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antimicrobial Antiviral
HIV-1
Monkey serum: Half-life is 9.6 h
PaperDwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. PMID:17640899 https://pubmed.ncbi.nlm.nih.gov/17640899/ PMID17640899 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17640899/
RECORD: Rec_0239442 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral
098 virus
0.118 μg/mL
IC50
Male cynomolgus monkey blood plasma (Intravenous), in vivo; 34560 s
PaperDesign of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus PMID17640899 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17640899/
FIRST PREV 1 2 3 4 NEXT LAST
Showing 5 records on this page · Page 2 of 4